Call your doctor for medical advice about side effects.

By using this Site you agree to the following 40 aluminum lake, magnesium stearate, and povidone.The chemical name for levonorgestrel is [18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17α)-(-)-]. The recommended dosage of LNG/EE Tablets is one tablet daily for 28 consecutive days: one white active tablet daily during the first 21 consecutive days, followed by one peach inactive tablet daily during the 7 following days (see Instruct patients about the handling of missed doses (e.g., to take a missed tablet as soon as possible) and to follow the dosing instructions provided in the FDA-approved patient labeling (Instructions for Use).If vomiting or acute diarrhea occurs within 3 to 4 hours after taking an active tablet, take the new active tablet (scheduled for the next day) as soon as possible. Specifically, thyroid-binding globulin (TBG) may be increased, resulting in elevated circulating total thyroid hormone, as measured by PBI (protein-bound iodine), T4 by column or radioimmunoassay, or T3 by radioimmunoassay. CYP3A inhibitors such as itraconazole, voriconazole, fluconazole, grapefruit juiceSignificant decreases in systemic exposure of the estrogen and/or progestin have been noted when CHCs are co-administered with some HIV protease inhibitors (e.g., nelfinavir, ritonavir, darunavir/ritonavir, (fos)amprenavir/ritonavir, lopinavir/ritonavir, and tipranavir/ritonavir), some HCV protease inhibitors (e.g., boceprevir and telaprevir), and some non-nucleoside reverse transcriptase inhibitors (e.g., nevirapine).In contrast, significant increases in systemic exposure of the estrogen and/or progestin have been noted when CHCs are co-administered with certain other HIV protease inhibitors (e.g., indinavir and atazanavir/ritonavir) and with other non-nucleoside reverse transcriptase inhibitors (e.g., etravirine).Table 4 provides significant drug interaction information for drugs co-administered with LNG/EE Tablets.The use of CHCs may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins.CHCs are contraindicated for use with Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir There is no use for contraception in pregnancy; therefore, LNG/EE Tablets should be discontinued during pregnancy. See "What should I do if I miss any LNG/EE Tablets" section in FDA-approved patient labeling CHCs may reduce breast milk production; this is less likely to occur if breastfeeding is well established Advise women that amenorrhea may occur. In patients requiring contraception, alternative methods should be considered for those who are hypertensive, over age 35, and smoke.Major Potential Hazard, High plausibility. However, based on the known pharmacokinetic effects of these drugs, clinical strategies to minimize any potential adverse effect on contraceptive effectiveness or safety are suggested.Consult the approved product labeling of all concurrently used drugs to obtain further information about interactions with CHCs or the potential for metabolic enzyme or transporter system alterations.No drug-drug interaction studies were conducted with LNG/EE Tablets.Co-administration of atorvastatin or rosuvastatin and CHCs containing ethinyl estradiol increase systemic exposure of ethinyl estradiol by approximately 20 to 25 percent.
Patients with a history of depression receiving estrogen and/or progestogen therapy should be followed closely. The failure rate may increase when tablets are missed or taken incorrectly. There is controversy about the extent to which these findings are due to differences in sexual behavior and other factors.The estrogen component of LNG/EE Tablets may raise the serum concentrations of thyroxine-binding globulin, sex hormone-binding globulin, and cortisol-binding globulin. These data included patients who did not take LNG/EE Tablets correctly. CHCs can reduce milk production in breast-feeding females.


Estrogens should be avoided in patients with a history of thrombotic and thromboembolic disorders associated with estrogen use, except when used in the treatment of breast or prostatic malignancy.Major Potential Hazard, High plausibility. Melasma (also known as chloasma faciei,: 854 or the mask of pregnancy when present in pregnant women) is a tan or dark skin discoloration.Melasma is thought to be caused by sun exposure, genetic predisposition, hormone changes, and skin irritation. I don't know how or why, but it was gone!